Monday, July 31, 2017

Kezar Life Sciences Raises $50M In Series B

South San Francisco-based Kezar Life Sciences said last week that it has raised $50M in a Series B funding. The funding was led by Cormorant Asset Management and Morningside Venture, and also included Cowen Healthcare Investments, Pappas Ventures, Qiming Venture Partners and Bay City Capital, plus EcoR1 Capital, Omega Funds, and Aju IB Investment. Kezar's lead drug candidate is a selective immunoproteasome inhibitor, aimed at treating multiple myeloma. The company says it has now raised $73M in total since 2015. More information »